{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-085548","form_type":"8-K","ticker":null,"cik":"0001797768","company_name":"Kinnate Biopharma Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.158673+00:00","generated_at":"2026-06-04T02:55:21.874941+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"XOMA completes acquisition of Kinnate for $2.5879/share plus CVR; trading halted","bullets":["38.3M shares (81%) tendered in offer; all conditions satisfied; merger effective April 3, 2024.","Shareholders receive $2.5879 cash per share plus one non-transferable CVR per share.","All Kinnate directors and officers resigned; Owen Hughes (XOMA) becomes sole director and officer.","Kinnate requested Nasdaq to suspend trading and delist shares; expects deregistration on Form 15.","Outstanding stock options and RSUs vested and cancelled in exchange for cash and/or CVRs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-085548","json":"https://secwatch.observer/filing/0001193125-24-085548.json","markdown":"https://secwatch.observer/filing/0001193125-24-085548.md","text":"https://secwatch.observer/filing/0001193125-24-085548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/d651169d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:55:21.874941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12cc6fa8c8","claim":"Melissa Epperly resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2277fe6c94","claim":"Neha Krishnamohan resigned as other_named_officer at Kinnate Biopharma Inc..","evidence_excerpt":"each of Nima Farzan, Neha Krishnamohan and Mark Meltz resigned as officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"2b2400ee07","claim":"Helen Sabzevari resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2d7151bd6c","claim":"Carl Gordon resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3cc359f9ee","claim":"Owen Hughes was appointed as President, Treasurer and Secretary at Kinnate Biopharma Inc..","evidence_excerpt":"The sole officer of Merger Sub immediately prior to the Effective Time was Owen Hughes, serving as President, Treasurer and Secretary.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Treasurer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"5c53d2c94b","claim":"Nima Farzan resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5f66478879","claim":"Owen Hughes was appointed as Director at Kinnate Biopharma Inc..","evidence_excerpt":"The sole director of Merger Sub immediately prior to the Effective Time was Owen Hughes.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"82e7f9417b","claim":"Laurie Smaldone Alsup resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9e15d71e57","claim":"Michael Rome resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a44b83cfc2","claim":"Jill DeSimone resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a5782fbf91","claim":"James Tananbaum resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d11bf650ee","claim":"Mark Meltz resigned as other_named_officer at Kinnate Biopharma Inc..","evidence_excerpt":"each of Nima Farzan, Neha Krishnamohan and Mark Meltz resigned as officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"d64901604c","claim":"Keith Flaherty resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"da8a52677b","claim":"Nima Farzan resigned as other_named_officer at Kinnate Biopharma Inc..","evidence_excerpt":"each of Nima Farzan, Neha Krishnamohan and Mark Meltz resigned as officers of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"feedf8e467","claim":"Dean J. Mitchell resigned as Director at Kinnate Biopharma Inc..","evidence_excerpt":"each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"20f708a88a496181b51f58a0f486aa8aea934d05","claim":"Kinnate Biopharma Inc.: Amended and restated certificate of incorporation.","evidence_excerpt":"the Surviving Corporation’s certificate of incorporation was amended and restated in its entirety, as set forth on Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"7495cf5bdc773945a9ccedd89d664a7e69738c95","claim":"Kinnate Biopharma Inc.: Adopted bylaws of Merger Sub as bylaws of Surviving Corporation.","evidence_excerpt":"the bylaws of Merger Sub as in effect immediately prior to the Effective Time became the bylaws of the Surviving Corporation, as set forth on Exhibit 3.2 to this Current Report on Form 8-K and is incorporated herein by reference","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"1e70281b5aed0bc90272c1c4324e4129c14993b8","claim":"Kinnate Biopharma Inc. underwent a change of control involving XOMA Corporation for $2.5879 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2024-04-03).","evidence_excerpt":"3, 2024, Merger Sub completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.0001 per share (the “Shares”), in exchange for (i) $2.5879 in cash per Share (the “Cash Amount”), plus (ii) one non-transferable contractual contingent value right per Share (each, a “CVR” and each CVR together with the Cash Amount, the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000119312524085548/0001193125-24-085548-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"XOMA Corporation"},{"label":"Consideration","value":"$2.5879 in cash per Share plus one non-transferable contractual contingent value right per Share"},{"label":"Closing","value":"2024-04-03"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}